We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+0.5%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.29B
AUM Growth
-$103M
Cap. Flow
+$24.5M
Cap. Flow %
0.75%
Top 10 Hldgs %
70.15%
Holding
85
New
9
Increased
10
Reduced
4
Closed
19

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$56.5M
2
ACET icon
Adicet Bio
ACET
+$55.5M
3
ZYME icon
Zymeworks
ZYME
+$53.2M
4
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$36.9M
5
DYN icon
Dyne Therapeutics
DYN
+$26.9M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$70.9M
2
GOSS icon
Gossamer Bio
GOSS
+$49.8M
3
RNAM
Avidity Biosciences
RNAM
+$47.3M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$39.1M
5
DSGN icon
Design Therapeutics
DSGN
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.78%
2 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRNX icon
26
Crinetics Pharmaceuticals
CRNX
$8.87B
$24.3M 0.74%
1,330,263
– –
ORIC icon
27
Oric Pharmaceuticals
ORIC
$1.24B
$20.1M 0.61%
3,418,068
– –
KYMR icon
28
Kymera Therapeutics
KYMR
$9.05B
$19.9M 0.6%
796,093
– –
LENZ
29
LENZ Therapeutics
LENZ
$179M
$19M 0.58%
816,014
+589,995
+261% +$13.7M
JANX icon
30
Janux Therapeutics
JANX
$950M
$18.7M 0.57%
1,421,319
– –
KDNY
31
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$18.1M 0.55%
690,000
– –
CNTA
32
DELISTED
Centessa Pharmaceuticals
CNTA
$16.2M 0.49%
5,232,279
+1,995,927
+62% +$7.4M
PSTX
33
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$14M 0.43%
2,650,000
– –
VTYX
34
DELISTED
Ventyx Biosciences
VTYX
$13.1M 0.4%
400,000
– –
OVID icon
35
Ovid Therapeutics
OVID
$439M
$11.4M 0.35%
6,117,400
– –
PRME icon
36
Prime Medicine
PRME
$544M
$11.1M 0.34%
+600,000
New +$10.8M
CGEM icon
37
Cullinan Oncology
CGEM
$1.07B
$10.9M 0.33%
1,035,038
-108,180
-9% -$1.31M
TSVT
38
DELISTED
2seventy bio
TSVT
$10.7M 0.33%
1,143,494
-1,197,819
-51% -$16.9M
GERN icon
39
Geron
GERN
$949M
$9.75M 0.3%
4,028,507
+1,726,527
+75% +$3.87M
AVEO
40
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$9.72M 0.3%
650,489
– –
BCAB icon
41
BioAtla
BCAB
$5.64M
$9.28M 0.28%
+22,489
New +$9.33M
DSGN icon
42
Design Therapeutics
DSGN
$742M
$9.08M 0.28%
884,903
-1,634,365
-65% -$22.1M
GRCL
43
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$7.69M 0.23%
3,343,202
+1,421,892
+74% +$4.36M
MGNX icon
44
MacroGenics
MGNX
$254M
$7.5M 0.23%
1,117,455
+186,500
+20% +$1.02M
IMTX icon
45
Immatics
IMTX
$1.18B
$6.47M 0.2%
+743,000
New +$7.69M
ARQT icon
46
Arcutis Biotherapeutics
ARQT
$3.48B
$6.15M 0.19%
415,322
– –
DTIL icon
47
Precision BioSciences
DTIL
$187M
$5.99M 0.18%
167,866
– –
OBIO icon
48
Orchestra BioMed
OBIO
$229M
$3.99M 0.12%
400,000
– –
RNAC icon
49
Cartesian Therapeutics
RNAC
$229M
$3.96M 0.12%
116,667
– –
PRAX icon
50
Praxis Precision Medicines
PRAX
$8.8B
$3.77M 0.11%
105,688
+5,933
+6% +$185K
1
2
3 4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q4 2022 Portfolio in Review

As of Q4 2022, EcoR1 Capital held 85 positions worth $3.29B, down 3% from $3.39B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

EcoR1 Capital's Q4 2022 filing shows 9 new, 10 increased, 4 reduced and 19 closed positions. Its largest new stake was Adicet Bio: 222,544 shares worth $31.8M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $70.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

  • EcoR1 Capital's largest Q4 2022 buy was Adicet Bio: 222,544 shares worth $31.8M.
  • EcoR1 Capital added most to Revolution Medicines in Q4 2022, an estimated $56.5M increase.
  • EcoR1 Capital's biggest Q4 2022 reduction was Design Therapeutics, cutting an estimated $22.1M.
  • EcoR1 Capital fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2022, selling an estimated $70.9M.
  • EcoR1 Capital's ten largest holdings make up 70% of its $3.29B portfolio in Q4 2022.
  • EcoR1 Capital opened 9 new positions and closed 19 in Q4 2022.
  • EcoR1 Capital's portfolio value fell 3% quarter-over-quarter to $3.29B.

Based on EcoR1 Capital's 13F filing for Q4 2022, filed 14 Feb 2023.